Back to results
US 9,267,946 B2Granted
Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
AssigneesInserm (Institut National De La Sante Et De La Rec, Universite De La Mediterranee - Aix-Marseille 11
InventorsIsabelle Auger, Jean Roudier
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects.
Claims5
A kit for detecting the presence of anti-PAD4 autoantibodies or anti-BRAF autoantibodies in a biological sample, said kit comprising:
- at least one biomarker,
- wherein the at least one biomarker is a PAD4-peptide (i) selected from the group consisting of SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, and SEQ ID NO:
- 5, or (ii) consisting of a fragment of PAD4 of less than 50 amino acids and comprising a sequence selected from the group consisting of SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, and SEQ ID NO:
- 5, or
- wherein the at least one biomarker is a BRAF-peptide (i) selected from the group consisting of SEQ ID NO:
- 7, SEQ ID NO:
- 8, and SEQ ID NO:
- 9, or (ii) consisting of a fragment of BRAF catalytic domain of less than 50 amino acids and comprising a sequence selected from the group consisting of SEQ ID NO:
- 7, SEQ ID NO:
- 8, and SEQ ID NO:
- 9;
- and
- at least one reagent for detecting a biomarker-antibody complex formed between the biomarker and an autoantibody present in the biological sample, wherein the autoantibody is an anti-PAD4 autoantibody or an anti-BRAF autoantibody that is indicative of rheumatoid arthritis, and wherein the at least one reagent is an anti-human IgG labelled with a detectable moiety.
16 more elements
Dependencies are inferred from the claim text.